Cidara Therapeutics, Inc. - Common Stock (NQ:CDTX)

219.88 +0.13 (+0.06%)

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cidara Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

March 02, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

March 01, 2023

Via Benzinga

Johnson & Johnson-Backed Antiviral Candidate Effectively Prevents Influenza Infection ↗

March 01, 2023

Cidara Therapeutics Inc (NASDAQ: CDTX) announced efficacy and safety data from a planned interim analysis of the ongoing Phase 2a trial evaluating the pre-exposure prophylactic activity of CD388...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

January 25, 2023

Via Benzinga

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

January 25, 2023

From Melinta Therapeutics, LLC

Via Business Wire

Looking Into Cidara Therapeutics's Return On Capital Employed ↗

November 25, 2022

Via Benzinga

Cidara's Lead Antifungal Candidate Goes Under Priority FDA Review ↗

September 21, 2022

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 24, 2023

Via Benzinga

Why FARO Technologies Shares Are Trading Lower By 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

January 20, 2023

Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 133.1% to $0.2870. Helbiz recently announced discontinuation of operations in non-profitable markets.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

January 20, 2023

Via Benzinga

Recap: Cidara Therapeutics Q2 Earnings ↗

August 09, 2022

Cidara Therapeutics (NASDAQ:CDTX) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

With FDA Submission, Cidara Therapeutics Inks US Pact For Bloodstream Infection Candidate ↗

July 27, 2022

Via Benzinga

Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗

December 27, 2022

Biopharma stocks were not immune to the broader market downturn seen for much of 2022.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 07, 2022

Gainers Cidara Therapeutics (NASDAQ:CDTX) shares rose 14.6% to $0.64 during Monday's pre-market session. The market value of their outstanding shares is at $44.9 million. The company's, Q3 earnings...

Via Benzinga

Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2022

October 17, 2022

From Cidara Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

October 10, 2022

Gainers NeuroMetrix (NASDAQ:NURO) shares increased by 23.0% to $3.48 during Monday's pre-market session. The company's market cap stands at $24.8 million.

Via Benzinga

Cidara Therapeutics Receives $11.1 Million Milestone Payment from Mundipharma

October 04, 2022

From Cidara Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

September 20, 2022

Gainers CinCor Pharma (NASDAQ:CINC) shares moved upwards by 19.5% to $33.0 during Tuesday's after-market session. The market value of their outstanding shares is at $1.4 billion.

Via Benzinga

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary ↗

September 13, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

September 07, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 17, 2022

Via Benzinga

Short Volatility Alert: Cidara Therapeutics, Inc. ↗

August 05, 2022

On Thursday, shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) experienced volatile short activity. After the activity, the stock price went down -3.74% to $0.72. The overall sentiment for CDTX has...

Via Benzinga

Short Volatility Alert: Cidara Therapeutics, Inc. ↗

August 01, 2022

On Friday, shares of Cidara Therapeutics, Inc. (NASDAQ: CDTX) experienced volatile short activity. After the activity, the stock price went up +7.53% to $0.785. The overall sentiment for CDTX has been...

Via Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary ↗

July 27, 2022

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 27, 2022

Via Benzinga

Cidara Pursues FDA Approval For Bloodstream Infections Candidate ↗

July 27, 2022

Cidara Therapeutics, Inc. (NASDAQ: CDTX) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its lead asset Rrezafungin for the treatment of candidemia and...

Via Benzinga

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy ↗

July 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 27, 2022

Via Benzinga

Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.

July 27, 2022

From Cidara Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 25, 2022

Gainers

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.